November 5, 2024 C-Path Scientific Directors Belmonte, Kosinski to Present at 20th IDS Congress Paul Belmonte, C-Path’s Scientific Director, T1D Consortium, and Luke Kosinski, Director, Quantitative Medicine, will present...
September 30, 2024 TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction...
October 8, 2024 Flexible approaches to eCOA administration in clinical trials: The site perspective Estelle Haenel, Celeste A. Elash, Katie Garner, Megan Turner, Scottie KernAbstract Electronic Clinical Outcome Assessment (eCOA) C
October 2, 2024 From Words to Action: Ensuring True Accessibility at Scientific Conferences I want to talk about access and inclusion at scientific conferences and putting actions to words or values. Conferences are...
October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB. Antibiotic resist
September 30, 2024 C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies C-Path announced the formation of a new task for under its RDCA-DAP, dedicated to...
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
September 12, 2024 Steve Gleason Welcomes Guests to Day 2 of #CGIC24 Former NFL player and ALS patient advocate welcomes attendees to the second day of C-Path’s Global Impact Conference.
September 12, 2024 C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development C-Path successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024.
September 9, 2024 FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) biomarker...